Fabry Disease: Patients Real-World Problems and How to Manage @checkrare
Fabry Disease: Patients Real-World Problems and How to Manage  @checkrare
Uploaded September 2026 | Updated November 2026, 3 hours ago
This educational program, hosted by Dawn Laney, MS, CGC, CCRC, Genetic Counselor and Program Leader for the Lysosomal Storage Disease Center at Emory University, and Staci Kallish, DO, Associate Professor of Clinical Medicine in the Division of Translational Medicine and Human Genetics at the University of Pennsylvania, examines how best to respond to patients concerns about how their Fabry disease, and its comorbidities, are managed. This program features a dialogue between patients who express their unmet needs, while two renowned Fabry disease experts translate these challenges into actionable clinical strategies.

Topics covered include 1) symptoms that patients believe are not being well managed by their medical team, 2) whether the risk of stroke or heart failure is being properly addressed by medical teams, 3) whether the risk of kidney failure is being properly addressed by medical teams, and 4) how well the medical team works together and understands Fabry disease.

This educational program is a non-CME activity made possible by an unrestricted grant from Amicus Therapeutics


Faculty
Dawn Laney, MS, CGC, CCRC
Genetic Counselor, Division of Medical Genetics
Program Leader, Lysosomal Storage Disease Center
Emory University School of Medicine
Disclosures
Consulting agreements: Amicus Therapeutics, Chiesi, Sanofi
Member: North American and International Fabry Registry Boards

Staci Kallish, DO
Associate Professor of Clinical Medicine
Division of Translational Medicine and Human Genetics
Perelman School of Medicine, University of Pennsylvania
Disclosures
Research grants: ashibio, Astellas Pharma, , Amicus Therapeutics
Idorsia Therapeutics, Incyte , Ipsen, and Sanofi
Consulting: Amicus Therapeutics, Sanofi
Advisory board: Amicus Therapeutics, Intrabio, Sanofi
Speaking honoraria: Amicus Therapeutics, Astellas, Sanofi

Learning Objectives
Upon completion of this program, participants will be able to:
• Recognize the real-world burdens facing Fabry patients and implement strategies to alleviate them.
• Identify and overcome barriers to managing heart concerns in patients with Fabry disease.
• Identify and overcome barriers to managing kidney concerns in patients with Fabry disease.
• Orchestrate a cohesive, multidisciplinary team approach to care.
Fabry Disease: Patients Real-World Problems and How to ManageLipodystrophy Research Presented at ENDO 2026Diagnosis and Treatment of IGF-1 DeficiencyPhase 2a GATEWAY Trial of PORT-77 in Patients With Erythropoietic Protoporphyria Shows PromiseEpisode 1: FDA Advisory Board’s Concerns About New Duchenne Drug, Brain Fog in Immune Thrombocyto...Approval of Imaavy (Nipocalimab) and its Impact on Patients With Warm Autoimmune Hemolytic AnemiaFDA Approves Multiple Myeloma Drug;  FDA Denies Neuroendocrine Drug; Safety Concerns For Prader-W...Follow-Up Data of Safusidenib in Patients With IDH-Mutant GliomasWhat the Approval of IMAAVY Means for Patients With wAIHAUltragenyx Sells PRV for $210M | The CheckRare Brief Ep 11Fabry Disease: Is The Risk of Stroke or Heart Failure Being Properly Managed By Your Medical Team?Inhaled Treprostinil Reduces Multiple Disease Progression Events in IPF
CheckRare |

Fabry Disease: Patients' Real-World Problems and How to Manage

SHARE TO X SHARE TO REDDIT SHARE TO FACEBOOK WALLPAPER